First author | age | sex | IEP | IF | EM | Aetiology | treatment | outcome | ||
---|---|---|---|---|---|---|---|---|---|---|
1 | 2003 | Touchard [20] | 48 | M | no | IgG3λ | subepi, subendo, mes | Idiopathic | PSL, Melphalan | remission |
2 | 2003 | Evans [21] | 81 | F | n/a | IgG1κ | subepi | ML (B cell) | PSL, CY, Chlorambucil | dead |
3 | 2004 | Nasr [1] | 63 | F | IgGλ | IgG1κ | subepi, subendo, mes | Idiopathic | n/a | |
4 | 42 | M | no | IgG1κ | subepi, subendo | Idiopathic | PSL | decreased proteinuria | ||
5 | 2008 | Komatsuda [2] | 44 | M | no | IgG3κ | subepi | Idiopathic | mPSL, PSL | decreased proteinuria |
6 | 24 | M | no | IgG3κ | subepi, subendo, mes | Idiopathic | PSL | decreased proteinuria | ||
7 | 2010 | Miura [15] | 61 | M | no | IgA1λ | subepi | HCV, cancer | Operation, Anti-tumor drug | no change |
8 | 2010 | de Seigneux [22] | 62 | F | IgGλ | IgG1λ | subepi, subendo | MGUS | Dexamethasone, Thalidomide | remission |
9 | n/a | n/a | no | IgG1κ | n/a | CLL | CY, Fludarabine | remission | ||
10 | n/a | n/a | no | IgG1κ | n/a | Unknown | PSL | ESRD | ||
11 | 2011 | Guiard [23] | n/a | n/a | IgGλ | IgG1λ | n/a | MM | PSL, Melphalan | remission |
12 | n/a | n/a | no | IgG2κ | n/a | Unknown | Rituximab | remission | ||
13 | n/a | n/a | no | IgG3κ | n/a | Unknown | PSL, CY | remission | ||
14 | n/a | n/a | no | IgG3κ | n/a | Unknown | Rituximab | decreased proteinuria | ||
15 | 2012 | Yamada [24] | 63 | M | no | IgG1λ | subepi | HCV | PSL, Mizoribine | decreased proteinuria |
16 | 2012 | Ito [25] | 68 | F | no | IgG3λ | subepi, mes | MPO-ANCA | PSL | remission |
17 | 2013 | Ohashi [26] | 27 | F | no | IgG2κ | subepi, mes | Idiopathic | PSL | remission |
18 | 2014 | Omokawa [16] | 62 | F | no | IgG4κ | subepi, mes | IgG4RD(lung) | mPSL, PSL | decreased proteinuria |
19 | 2017 | Present case | 65 | M | no | IgA1λ | subepi | IgG4RKD(TIN) | PSL | no change |